News

New Data from Key Trial of Kyprolis to Treat Advanced Multiple Myeloma Shows Benefits

Amgen reported findings from a post-hoc analysis of the pivotal Phase 3 ASPIRE clinical trial, highlighting the continued benefits of carfilzomib (Kyprolis), a second-generation proteasome inhibitor, plus a standard two-drug regimen (lenalidomide and dexamethasone) in relapsed multiple myeloma patients. The findings were presented during the recent 21st Congress of the European Hematology Association (EHA) in Denmark. A separate sub-analyses…

Positive Results from Phase 3 Trial of Combo Therapy for Multiple Myeloma Presented at ASCO 2016

Researchers from Janssen Research & Development presented promising interim results from the Phase 3 MMY3004 (CASTOR) clinical trial, assessing the immunotherapy drug daratumumab (Darzalex) against standard of care in previously treated multiple myeloma patients, at the recent American Society of Clinical Oncology (ASCO) 2016 Annual Meeting in Chicago. Specifically, the ongoing trial (NCT02136134) showed…

Study Reveals Multiple Myeloma Treatment Disparities Between Caucasian, African-American Patients

Celgene Corporation recently presented a study comparing overall survival, treatment patterns, and healthcare costs between Caucasian (white-skinned) and African-American Medicare beneficiaries who were diagnosed with multiple myeloma, revealing there are discrepancies in treatment initiation between the two patient populations and discussing the impact of these inequalities on clinical outcomes. The study was presented at…

Revlimid Maintenance Following Stem Cell Transplant in Multiple Myeloma Patients Appears to Improve Overall Survival

Researchers at Buffalo, New York’s Roswell Park Cancer Institute (RPCI) have showed that maintenance lenalidomide (marketed as Revlimid) following autologous hematopoietic stem cell (HSC) transplant improves the overall survival of multiple myeloma patients. The findings from the study “Lenalidomide (LEN) maintenance (MNTC) after high-dose melphalan and autologous stem cell…

ASCO 2016: Updated Data of MOR202 for Multiple Myeloma Presented by MorphoSys

In a poster presentation at the 2016 ASCO Annual Meeting in Chicago, MorphoSys presented updated safety and efficacy data from an ongoing open-label, multicenter, Phase 1/2a clinical trial investigating MOR202 monotherapy in combination with lenalidomide (Len) and pomalidomide (Pom) plus dexamethasone (Dex) in 63 patients with relapsed/refractory multiple myeloma…